NEW YORK, March 9, 2022 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage
biopharmaceutical company developing novel products to treat brain
health disorders, today announced that Robert Barrow, Chief Executive Officer and
Director, will participate in the following upcoming investor
conferences in March:
34th Annual Roth Conference
Format: Panel –
Psychedelics: "Immunotherapy" for the Mind
Date: Tuesday, March 15 at
10:00 AM PST / 1:00 PM EST
Webcast Link: Click Here
Oppenheimer Virtual Annual Healthcare
Conference
Format: Corporate Presentation
Date: Thursday, March 17 at
12:40 PM EST
Webcast Link: Click Here
Maxim Virtual Growth Conference
Format: Corporate
Presentation
Date: March 28-30, 2022
Further Info: Click Here
A replay of the webcasts will be available in the "Investors"
section of MindMed's website for 30 days following each of the
presentations.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing
novel products to treat brain health disorders, with a particular
focus on psychiatry, addiction, pain and neurology. Our mission is
to be the global leader in the development and delivery of
treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-march-investor-conferences-301498744.html
SOURCE Mind Medicine (MindMed) Inc.